ARTICLE | Finance
Public Equity Report: French biotech to fund MASH study with €348M lifeline; bispecifics developer raises $250; DMD cardiomyopathy play prices follow-on
By Paul Bonanos, Director of Biopharma Intelligence
October 19, 2024 12:28 AM UTC
With its cash pile shrinking, Inventiva S.A. (Euronext: IVA; NASDAQ:IVA) forged a tranched deal with an investor syndicate that will drive late-stage testing of lanifibranor to treat metabolic dysfunction-associated steatohepatitis.
The French biotech will immediately receive €94.1 million ($102.1 million) from a syndicate led by New Enterprise Associates, BVF Partners and Samsara BioCapital. If conditions are met in the future, the deal could supply Inventiva with a total of €348 million from the investors, plus another $30 million under a separate licensing agreement with Chia Tai Tianqing Pharmaceutical (Guangzhou) Co. Ltd…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653907/cash-raises-for-inventiva-akeso-capricor